Clinical Trials Logo

Neuroendocrine Tumor Grade 2 clinical trials

View clinical trials related to Neuroendocrine Tumor Grade 2.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06395402 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

LUMOD-ID
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to learn if individualized dosimetry-based prescribing of Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals) improves treatment outcomes for adults with unresectable neuroendocrine tumors. To investigate this, study participants will: - Undergo Somatostatin Receptor (SSTR) positron emission tomography (PET) imaging, such as a DOTATOC PET/CT scan - Be randomized to receive standard treatment (as per FDA guidelines) or investigational treatment (customized dosing of Lutathera based upon dosimetry) - Undergo blood tests for 4 to 8 weeks after each Lutathera treatment - Complete patient reported outcome questionnaires - Visit the clinic for follow-up about every 8 weeks.